Monoclonal Antibodies Market Poised to Hit USD 612.2 Bn by 2032 — Acumen Report Signals 12.3% CAGR

PORTLAND, Ore. - Dec. 12, 2025 - PRLog -- According to the latest research by Acumen Research and Consulting (ARC), the global Monoclonal Antibodies Market — a cornerstone of modern biologic therapies — is on track for dramatic expansion. The Monoclonal Antibodies Market Report estimates that the market, valued at USD 195.6 billion in 2022, will surge to USD 612.2 billion by 2032, registering a robust compound annual growth rate (CAGR) of 12.3% between 2023 and 2032.

Key Statistics from Monoclonal Antibodies Market Report

• Market Size (2022): USD 195.6 billion
• Projected Market Size (2032): USD 612.2 billion
• Forecast Period (CAGR 2023–2032): 12.3%
• Largest Region (2022): North America — over USD 91.9 billion
• Leading End-Use Segment (2022): Hospitals — over 54% share
• Dominant Source Type (2022): Human-derived monoclonal antibodies — contributing over USD 99.7 billion in revenue

Download Free PDF Sample Report: https://ln.run/vsOuY

Why Monoclonal Antibodies Market Is Gaining Momentum

Report identifies several critical factors driving Monoclonal Antibodies Market Growth:

• Rising burden of chronic diseases and cancers: As incidence of cancer, autoimmune diseases, and infectious diseases increase globally, demand for targeted biologic therapies like monoclonal antibodies surges.
• Expanding pharmaceutical R&D and biologics innovation: Advances in antibody engineering, conjugation technologies, and novel therapeutic formats (e.g., antibody-drug conjugates, bispecific antibodies) are broadening the application scope and improving efficacy.
• Growing accessibility via hospitals and healthcare infrastructure: With hospitals accounting for the majority share of end-use, improved healthcare delivery and adoption globally fuel market penetration.

These drivers position the Monoclonal Antibodies Market as a key pillar in modern therapeutic landscapes — enabling better patient outcomes and targeted treatment approaches.

Market Segmentation & Regional Outlook

Monoclonal Antibodies Market Analysis covers segmentation by Source Type, Application, End-Use, Clinical Use, Region, and more.

• By Source Type: Human-derived monoclonal antibodies lead the market, reflecting widespread clinical adoption and trust due to lower immunogenicity and better safety profiles.
• By End-Use: Hospitals remain the major consumers of monoclonal antibody therapies — driven by rising chronic disease burden, availability of treatment infrastructure and growing therapeutic adoption.
• By Geography: North America currently dominates, supported by advanced healthcare infrastructure, high R&D investment, and presence of key biopharma players. Asia-Pacific, Europe, Latin America and Middle East & Africa are covered in the regional scope — with Asia-Pacific expected to register significant growth as access and healthcare investment increase.

Read Full News at Globenewswire: https://www.globenewswire.com/news-release/2023/09/06/2738625/0/en/Monoclonal-Antibodies-Market-is-expected-to-reach-USD-612-2-Billion-by-2032-growing-at-a-CAGR-of-12-3-from-2022-to-2032.html